Related Experiment Video

Updated: Aug 15, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia

Stephanie R Earnshaw1, Sean D Candrilli, Ancilla W Fernandes

  • 1Health Economics of RTI Health Solutions, Research Triangle Park, North Carolina 27709, USA. searnshaw@rti.org

Managed Care Interface
|November 4, 2005
PubMed

Insights

Amoxicillin/clavulanate extended-release (AMX/CLA ER) offers a more cost-effective treatment for community-acquired pneumonia (CAP) than clarithromycin ER. AMX/CLA ER achieved higher cure rates and lower costs, addressing rising antibiotic resistance concerns.

Area of Science:

  • Pharmacoeconomics and Infectious Disease Management
  • Antimicrobial Resistance and Treatment Efficacy

Background:

  • Community-acquired pneumonia (CAP) treatment success is critical, yet rising Streptococcus pneumoniae antibiotic resistance complicates first-line therapies.
  • The increasing prevalence of resistant S. pneumoniae necessitates evaluating alternative treatment strategies for CAP.

Purpose of the Study:

  • To analyze the cost-effectiveness and budgetary impact of treating CAP using amoxicillin/clavulanate (AMX/CLA) extended-release (ER) versus clarithromycin ER.
  • To compare clinical cure rates and average treatment costs between AMX/CLA ER and clarithromycin ER for CAP.

Main Methods:

  • A pharmacoeconomic model was developed, incorporating the incidence of macrolide- and AMX/CLA-susceptible and nonsusceptible S. pneumoniae.
  • Clinical cure rates were derived from multicenter trials and published literature to calculate average treatment costs and success rates.

Main Results:

  • Amoxicillin/clavulanate ER demonstrated a higher clinical cure rate (88.7%) compared to clarithromycin ER (82.4%).
  • Amoxicillin/clavulanate ER resulted in significantly lower average per-patient treatment costs ($437.70) versus clarithromycin ER ($548.14).

Conclusions:

  • Amoxicillin/clavulanate ER is a more effective and cost-effective treatment option for CAP compared to clarithromycin ER.
  • These findings support the use of AMX/CLA ER in managing CAP, particularly in the context of increasing antimicrobial resistance.

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: